特拉万星治疗间歇性血液透析患者难治性MRSA菌血症
本研究为两所三级学术医疗中心的回顾性研究,纳入接受特拉万星单药治疗的复发或持续性(≥3天)MRSA菌血症住院患者。特拉万星按10 mg/kg透析后每周三次或10 mg/kg每48小时给药,8例难治性MRSA菌血症中7例(87.5%)获得微生物学治愈,菌血症中位持续时间从用药前16天降至用药后1天(P=0.018),全部患者耐受良好且未报告不良事件。
要点
- 特拉万星10 mg/kg透析后每周三次或每48小时给药,8例中7例(87.5%)微生物学治愈。
- 菌血症中位持续时间用药前16天(IQR 8-19天)降至用药后1天(IQR 0-2天),P=0.018。
- 全部患者耐受良好,未报告不良事件。
核心结论
- 特拉万星在需间歇性血液透析的终末期肾病患者中治疗难治性MRSA菌血症非常安全且高度有效。
研究设计与样本
- 回顾性研究,纳入两所三级学术医疗中心的住院患者,均为复发或持续性(≥3天)MRSA菌血症并接受特拉万星单药治疗。
主要发现
- 特拉万星10 mg/kg透析后每周三次或10 mg/kg每48小时给药,8例难治性MRSA菌血症中7例(87.5%)获得微生物学治愈。
- 特拉万星单药治疗与菌血症中位持续时间显著缩短相关:用药前16天(IQR 8-19天)对比用药后1天(IQR 0-2天),P=0.018。
- 全部患者对特拉万星耐受良好,未报告不良事件。
临床怎么用
- 对于需间歇性血液透析的终末期肾病患者发生难治性MRSA菌血症,可考虑使用特拉万星单药治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with end-stage renal disease (ESRD) requiring intermittent haemodialysis (IHD) are at high risk of MRSA bacteraemia (MRSA-B) and often fail first-line therapy. The safety, effectiveness and optimal dosing of telavancin for MRSA-B in this patient population are unclear. OBJECTIVES: We aimed to describe clinical outcomes of telavancin in the treatment of refractory MRSA-B in patients with ESRD requiring IHD. PATIENTS AND METHODS: This was a retrospective study of hospitalized patients at two tertiary care academic medical centres with recurrent or persistent (≥3 days) MRSA-B treated with telavancin monotherapy. Outcomes included duration of MRSA-B (pre-telavancin versus post-telavancin) and microbiological failure (duration of MRSA-B ≥3 days after initiation of telavancin). RESULTS: Telavancin dosed 10 mg/kg three times weekly post-IHD or 10 mg/kg every 48 h resulted in microbiological cure in 7/8 (87.5%) refractory MRSA-B cases. Telavancin monotherapy was associated with a significant reduction in median duration of bacteraemia [16 days pre-telavancin (IQR 8-19 days) versus 1 day post-telavancin (IQR 0-2 days); P = 0.018]. Telavancin was well tolerated by all patients and no adverse events were reported. CONCLUSIONS: Telavancin was very safe and highly effective in the treatment of refractory MRSA-B in a cohort of patients with ESRD requiring IHD. These data support the utility of telavancin in the armamentarium against refractory MRSA-B, particularly in the high-risk IHD-dependent population.
引用
- Britt NS, Tirmizi S, Ritchie DJ, et al. Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients. J Antimicrob Chemother. 2018. PMID: 29244141. doi:10.1093/jac/dkx437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。